SIMPONI® to Arrest Beta-Cell Loss in Type 1 Diabetes
This study aims to determine if the drug SIMPONI® (golimumab) can preserve beta-cell function in children and young adults with newly diagnosed type 1 diabetes.
The T1GER study is investigating the effect of treatment with golimumab, a TNF alpha-blocker, on beta-cell function in children, adolescents, and young adults with newly diagnosed type 1 diabetes. This study will also evaluate the safety and tolerability of the study drug in individuals with type 1 diabetes.
Participation in the study includes a screening visit and 13 clinical site visits over approximately two years.
Recruitment: This study is not currently recruiting.
This study is no longer recruiting participants.
Principal Investigator: Dr. Jason Gaglia